[Intrathecal administration of amikacin in postoperative refractory meningitis].
The intrathecal administration of amikacin (AMK) (50--100 mg/day) was effective for 3 cases of postoperative refractory meningitis caused by gentamicin (GM) resistant organisms. The infecting pathogen of case 1 was K. pneumoniae and that of case 2 was S. epidermidis, while no pathogen was cultured in case 3. The causative pathogens in the former were eradicated only with AMK. No therapeutic response was gained with GM, but with AMK in the latter. High tone hearing impairment was observed in case 1 and transient vomiting was observed in case 3. However, these side effects were trivial for the severity of disease. It is suggested in these 3 cases that the high dose intrathecal administration of AMK may be extremely useful in the treatment of postoperative refractory meningitis which has shown no response to GM.
D000368:Aged; D000583:Amikacin / Q000008:administration & dosage* / Q000134:cerebrospinal fluid; D006801:Humans; D007278:Injections, Spinal; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy
D007612:Kanamycin; D000583:Amikacin